{"title":"Cidex®  ortho-phthalaldehyde (OPA) high level disinfectant solution - carry out risk assessment before use if there is no alternative","public_updated_at":"2014-12-17T14:52:19Z","details":{"metadata":{"alert_type":"devices","issued_date":"2004-05-26","medical_specialism":["critical-care","general-practice"],"bulk_published":true,"document_type":"medical_safety_alert"},"change_history":[],"body":[{"content_type":"text/html","content":"<p>Deadline (Action underway): 09 June 2004 Action plan to be agreed and actions started. \nDeadline (Action complete): 26 Nov 2004 All actions to be completed.</p>\n\n<h2 id=\"device\">Device</h2>\n\n<p>Cidex® OPA <em>ortho</em>-phthalaldehyde high level disinfectant solution manufactured by Advanced Sterilization Products (ASP) a Johnson &amp; Johnson company.</p>\n\n<h2 id=\"problem\">Problem</h2>\n<p>Repeated exposure to Cidex® OPA high level disinfectant solution, following manual re-processing of urological instruments, may have resulted in hypersensitivity in some patients with a history of bladder cancer undergoing repeated cystoscopy.</p>\n\n<p>Johnson &amp; Johnson has issued a Product Notification, contraindicating the use of Cidex® OPA for re-processing urological instrumentation for use in patients with a history of bladder cancer. A letter and revised instructions for use were issued on 27 April 2004 to all UK customers that have bought Cidex® OPA.</p>\n\n<p>A recent post-marketing surveillance review carried out by the company identified that, since the product was introduced in 1999, out of approximately 1 million urological procedures world-wide, there have been reports of 24 patients who have experience &lsquo;anaphylaxis-like&rsquo; reactions after repeated cystoscopy (typically after 4-9 treatments). Symptoms reported to the manufacturer included nausea, penile swelling, hypotension, vomiting, breathing difficulty, wheezing, rash, hives, eye irritation, dizziness and anaphylactic shock.</p>\n\n<p>In all of the above cases the manufacturer has indicated that the instruments had been manually re-processed. The evidence for manual re-processing being a significant risk factor is, therefore, compelling.</p>\n\n<h2 id=\"action\">Action</h2>\n\n<p>Where no validated alternative to Cidex® OPA is available and there is potential for repeated exposure, carry out a risk assessment and options appraisal, taking into account the following factors:</p>\n\n<h4 id=\"risk-factors-in-considering-risks-to-patients\">Risk factors in considering risks to patients:</h4>\n\n<ul>\n  <li>\n    <p>the risk of sensitisation is related to patterns of exposure. In this instance, repeated cystoscopy and ineffective removal of residues are important risk factors associated with the use of Cidex® OPA;</p>\n  </li>\n  <li>\n    <p>bladder cancer is associated with reactions to Cidex® OPA, but this is likely to be due to repeated cystoscopy, rather than a risk factor per se. Bladder cancer is not associated with increased susceptibility to allergic disease;</p>\n  </li>\n  <li>\n    <p>trauma associated with cystoscopy, particularly in male patients, may augment allergic reactions.</p>\n  </li>\n</ul>\n\n<h4 id=\"in-considering-risks-to-users\">In considering risks to users:</h4>\n\n<ul>\n  <li>\n    <p>the company has identified that healthcare workers have experienced irritation or possible allergic reactions due to exposure to Cidex® OPA. It is the company&rsquo;s view that, in most of these cases, the healthcare workers were not using the product in a manner consistent with the instructions for use;</p>\n  </li>\n  <li>\n    <p>symptoms reported in healthcare workers do not appear to be indicative of Type I hypersensitivity.</p>\n  </li>\n</ul>\n\n<p>Risk control measures: in the short term, residues of Cidex® OPA should be minimised, preferably by the use of a validated endoscope washer-disinfector cycle. If manual processing is carried out, ensure that the manufacturers&rsquo; instructions for use are followed, in particular during rinsing.</p>\n\n<p>It is not appropriate to use a sensitiser in circumstances where repeat exposure is a possibility and where such use is avoidable. It is therefore necessary to identify an alternative to Cidex® OPA, a suspected sensitiser, in circumstances where there is potential for repeated exposure to patients. Any alternative must be validated for use and compatible with the device and, where applicable, the endoscope washer-disinfector, in line with each of the respective manufacturer&rsquo;s instructions for use.</p>\n\n<p>Further advice on decontamination, including the selection of materials and processes, is available in MHRA Device Bulletin <a href=\"ssLINK/CON007329\">DB 2002(05) &lsquo;Decontamination of Endoscopes&rsquo;</a> and NHS Estates publication HTM 2030 &lsquo;Washer-Disinfectors - Design considerations&rsquo;.</p>\n\n<p>[Note: endoscope washer-disinfectors may also be described as automated endoscope re-processors (AER)]</p>\n\n<h2 id=\"action-by\">Action by</h2>\n\n<ul>\n  <li>Healthcare personnel using the above disinfectant</li>\n  <li>Healthcare personnel managing the above patients</li>\n</ul>\n\n<p>ACTION: When re-processing urological instruments for use inpatients who have potential for repeated exposure:</p>\n\n<ul>\n  <li>Do not use Cidex® OPA if a validated alternative is available.</li>\n  <li>If no validated alternative to Cidex® OPA is available:</li>\n  <li>\n    <ul>\n      <li>carry out a risk assessment on the continued use of this disinfectant solution;</li>\n    </ul>\n  </li>\n  <li>\n    <p>ensure that measures are in place to minimise disinfectant solution residues (e.g. use of a validated endoscope washer-disinfector);</p>\n  </li>\n  <li>plan and implement the replacement of this disinfectant solution with an alternative.</li>\n</ul>\n\n<h2 id=\"distribution\">Distribution</h2>\n\n<p>NHS Trusts (England) - Chief Executives\nHealthcare Commission (CHAI) - Headquarters \nPrimary Care Trusts (England) - Chief Executives </p>\n\n<p>Please bring this notice to the attention of all who need to know or be aware of it. This will included distribution by:</p>\n\n<p>TRUSTS to:</p>\n\n<ul>\n  <li>\n    <p>Liaison officers (for onward distribution)</p>\n  </li>\n  <li>\n    <p>Clinical governance leads</p>\n  </li>\n  <li>\n    <p>Consultant urologists</p>\n  </li>\n  <li>\n    <p>Decontamination leads</p>\n  </li>\n  <li>\n    <p>Endoscopy suite managers</p>\n  </li>\n  <li>\n    <p>Health &amp; safety officers</p>\n  </li>\n  <li>\n    <p>Infection control doctors</p>\n  </li>\n  <li>\n    <p>Infection control nurses</p>\n  </li>\n  <li>\n    <p>Medical directors</p>\n  </li>\n  <li>\n    <p>Nursing executive directors</p>\n  </li>\n  <li>\n    <p>Pharmacy managers</p>\n  </li>\n  <li>\n    <p>Risk managers</p>\n  </li>\n  <li>\n    <p>Sterile service managers</p>\n  </li>\n  <li>\n    <p>Theatre managers</p>\n  </li>\n  <li>\n    <p>Urology departments</p>\n  </li>\n</ul>\n\n<p>HEALTHCARE COMMISSION (CHAI) to:</p>\n\n<ul>\n  <li>\n    <p>Headquarters (for onward distribution)</p>\n  </li>\n  <li>\n    <p>Clinics</p>\n  </li>\n  <li>\n    <p>Hospices</p>\n  </li>\n  <li>\n    <p>Hospitals in the independent sector</p>\n  </li>\n  <li>\n    <p>Private medical practitioners</p>\n  </li>\n</ul>\n\n<p>PRIMARY CARE TRUSTS to:</p>\n\n<ul>\n  <li>\n    <p>Liaison officers (for onward distribution)</p>\n  </li>\n  <li>\n    <p>Clinical governance leads</p>\n  </li>\n  <li>\n    <p>Community hospitals</p>\n  </li>\n  <li>\n    <p>Directors of public health</p>\n  </li>\n  <li>\n    <p>Endoscopy suites</p>\n  </li>\n  <li>\n    <p>General medical practitioners</p>\n  </li>\n  <li>\n    <p>Infection control teams</p>\n  </li>\n  <li>\n    <p>Lead nurses</p>\n  </li>\n  <li>\n    <p>Practice nurses</p>\n  </li>\n</ul>\n\n<h2 id=\"manufacturer-contact\">Manufacturer contact</h2>\n\n<p>Enquiries to the manufacturer/suppler should be addressed to:</p>\n\n<div class=\"address\"><div class=\"adr org fn\"><p>\n\nCustomer Services\n<br />Advanced Sterilization Products (A Johnson &amp; Johnson company)\n<br />The Braccans\n<br />London Road\n<br />Bracknell\n<br />RG12 2AT\n<br />Tel: 0800 864 060\n<br />Fax: 01344 871 171\n<br />\n</p></div></div>\n\n<h2 id=\"england\">England</h2>\n\n<p>Enquiries to the MHRA should quote reference number <strong>2004/004/028/291/361</strong> and be addressed to:</p>\n\n<h4 id=\"technical-aspects\">Technical aspects</h4>\n<p>Ian Smith or Jill Dhell\nMedicines &amp; Healthcare products Regulatory Agency\nHannibal House\nElephant and Castle\nLondon SE1 6TQ</p>\n\n<p>Tel: 020 7972 8306 / 8268\nFax: 020 7972 8106</p>\n\n<p>E-mail:<a href=\"&#109;&#097;&#105;&#108;&#116;&#111;:&#105;&#097;&#110;&#046;&#115;&#109;&#105;&#116;&#104;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;\">&#105;&#097;&#110;&#046;&#115;&#109;&#105;&#116;&#104;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;</a><a href=\"&#109;&#097;&#105;&#108;&#116;&#111;:&#106;&#105;&#108;&#108;&#046;&#100;&#104;&#101;&#108;&#108;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;\">&#106;&#105;&#108;&#108;&#046;&#100;&#104;&#101;&#108;&#108;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;</a></p>\n\n<h4 id=\"clinical-aspects\">Clinical aspects:</h4>\n\n<p>Jonathan Plumb\nMedicines &amp; Healthcare products Regulatory Agency\nHannibal House\nElephant and Castle\nLondon \nSE1 6TQ</p>\n\n<p>Tel: 020 7972 8128\nFax: 020 7972 8103</p>\n\n<p>E-mail:<a href=\"&#109;&#097;&#105;&#108;&#116;&#111;:&#106;&#111;&#110;&#097;&#116;&#104;&#097;&#110;&#046;&#112;&#108;&#117;&#109;&#098;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;\">&#106;&#111;&#110;&#097;&#116;&#104;&#097;&#110;&#046;&#112;&#108;&#117;&#109;&#098;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;</a></p>\n\n"},{"content_type":"text/govspeak","content":"Deadline (Action underway): 09 June 2004 Action plan to be agreed and actions started. \r\nDeadline (Action complete): 26 Nov 2004 All actions to be completed.\r\n\r\n## Device\r\n\r\nCidex® OPA _ortho_-phthalaldehyde high level disinfectant solution manufactured by Advanced Sterilization Products (ASP) a Johnson & Johnson company.\r\n\r\n## Problem\r\nRepeated exposure to Cidex® OPA high level disinfectant solution, following manual re-processing of urological instruments, may have resulted in hypersensitivity in some patients with a history of bladder cancer undergoing repeated cystoscopy.\r\n\r\nJohnson & Johnson has issued a Product Notification, contraindicating the use of Cidex® OPA for re-processing urological instrumentation for use in patients with a history of bladder cancer. A letter and revised instructions for use were issued on 27 April 2004 to all UK customers that have bought Cidex® OPA.\r\n\r\nA recent post-marketing surveillance review carried out by the company identified that, since the product was introduced in 1999, out of approximately 1 million urological procedures world-wide, there have been reports of 24 patients who have experience 'anaphylaxis-like' reactions after repeated cystoscopy (typically after 4-9 treatments). Symptoms reported to the manufacturer included nausea, penile swelling, hypotension, vomiting, breathing difficulty, wheezing, rash, hives, eye irritation, dizziness and anaphylactic shock.\r\n\r\nIn all of the above cases the manufacturer has indicated that the instruments had been manually re-processed. The evidence for manual re-processing being a significant risk factor is, therefore, compelling.\r\n\r\n## Action\r\n\r\nWhere no validated alternative to Cidex® OPA is available and there is potential for repeated exposure, carry out a risk assessment and options appraisal, taking into account the following factors:\r\n\r\n#### Risk factors in considering risks to patients:\r\n\r\n* the risk of sensitisation is related to patterns of exposure. In this instance, repeated cystoscopy and ineffective removal of residues are important risk factors associated with the use of Cidex® OPA;\r\n\r\n* bladder cancer is associated with reactions to Cidex® OPA, but this is likely to be due to repeated cystoscopy, rather than a risk factor per se. Bladder cancer is not associated with increased susceptibility to allergic disease;\r\n\r\n* trauma associated with cystoscopy, particularly in male patients, may augment allergic reactions.\r\n\r\n#### In considering risks to users:\r\n\r\n* the company has identified that healthcare workers have experienced irritation or possible allergic reactions due to exposure to Cidex® OPA. It is the company's view that, in most of these cases, the healthcare workers were not using the product in a manner consistent with the instructions for use;\r\n\r\n* symptoms reported in healthcare workers do not appear to be indicative of Type I hypersensitivity.\r\n\r\nRisk control measures: in the short term, residues of Cidex® OPA should be minimised, preferably by the use of a validated endoscope washer-disinfector cycle. If manual processing is carried out, ensure that the manufacturers' instructions for use are followed, in particular during rinsing.\r\n\r\nIt is not appropriate to use a sensitiser in circumstances where repeat exposure is a possibility and where such use is avoidable. It is therefore necessary to identify an alternative to Cidex® OPA, a suspected sensitiser, in circumstances where there is potential for repeated exposure to patients. Any alternative must be validated for use and compatible with the device and, where applicable, the endoscope washer-disinfector, in line with each of the respective manufacturer's instructions for use.\r\n\r\nFurther advice on decontamination, including the selection of materials and processes, is available in MHRA Device Bulletin [DB 2002(05) 'Decontamination of Endoscopes'](ssLINK/CON007329) and NHS Estates publication HTM 2030 'Washer-Disinfectors - Design considerations'.\r\n\r\n[Note: endoscope washer-disinfectors may also be described as automated endoscope re-processors (AER)]\r\n\r\n## Action by\r\n\r\n* Healthcare personnel using the above disinfectant\r\n* Healthcare personnel managing the above patients\r\n\r\nACTION: When re-processing urological instruments for use inpatients who have potential for repeated exposure:\r\n\r\n* Do not use Cidex® OPA if a validated alternative is available.\r\n* If no validated alternative to Cidex® OPA is available:\r\n* * carry out a risk assessment on the continued use of this disinfectant solution;\r\n* ensure that measures are in place to minimise disinfectant solution residues (e.g. use of a validated endoscope washer-disinfector);\r\n\r\n* plan and implement the replacement of this disinfectant solution with an alternative.\r\n\r\n## Distribution\r\n\r\nNHS Trusts (England) - Chief Executives\r\nHealthcare Commission (CHAI) - Headquarters \r\nPrimary Care Trusts (England) - Chief Executives \r\n\r\nPlease bring this notice to the attention of all who need to know or be aware of it. This will included distribution by:\r\n\r\nTRUSTS to:\r\n\r\n* Liaison officers (for onward distribution)\r\n\r\n* Clinical governance leads\r\n\r\n* Consultant urologists\r\n\r\n* Decontamination leads\r\n\r\n* Endoscopy suite managers\r\n\r\n* Health & safety officers\r\n\r\n* Infection control doctors\r\n\r\n* Infection control nurses\r\n\r\n* Medical directors\r\n\r\n* Nursing executive directors\r\n\r\n* Pharmacy managers\r\n\r\n* Risk managers\r\n\r\n* Sterile service managers\r\n\r\n* Theatre managers\r\n\r\n* Urology departments\r\n\r\nHEALTHCARE COMMISSION (CHAI) to:\r\n\r\n* Headquarters (for onward distribution)\r\n\r\n* Clinics\r\n\r\n* Hospices\r\n\r\n* Hospitals in the independent sector\r\n\r\n* Private medical practitioners\r\n\r\nPRIMARY CARE TRUSTS to:\r\n\r\n* Liaison officers (for onward distribution)\r\n\r\n* Clinical governance leads\r\n\r\n* Community hospitals\r\n\r\n* Directors of public health\r\n\r\n* Endoscopy suites\r\n\r\n* General medical practitioners\r\n\r\n* Infection control teams\r\n\r\n* Lead nurses\r\n\r\n* Practice nurses\r\n\r\n## Manufacturer contact\r\n\r\nEnquiries to the manufacturer/suppler should be addressed to:\r\n\r\n\r\n$A\r\nCustomer Services\r\nAdvanced Sterilization Products (A Johnson & Johnson company)\r\nThe Braccans\r\nLondon Road\r\nBracknell\r\nRG12 2AT\r\nTel: 0800 864 060\r\nFax: 01344 871 171\r\n$A\r\n\r\n## England\r\n\r\nEnquiries to the MHRA should quote reference number **2004/004/028/291/361** and be addressed to:\r\n\r\n#### Technical aspects\r\nIan Smith or Jill Dhell\r\nMedicines & Healthcare products Regulatory Agency\r\nHannibal House\r\nElephant and Castle\r\nLondon SE1 6TQ\r\n\r\nTel: 020 7972 8306 / 8268\r\nFax: 020 7972 8106\r\n\r\nE-mail:[ian.smith@mhra.gsi.gov.uk](mailto:ian.smith@mhra.gsi.gov.uk)[jill.dhell@mhra.gsi.gov.uk](mailto:jill.dhell@mhra.gsi.gov.uk)\r\n\r\n#### Clinical aspects: \r\n\r\nJonathan Plumb\r\nMedicines & Healthcare products Regulatory Agency\r\nHannibal House\r\nElephant and Castle\r\nLondon \r\nSE1 6TQ\r\n\r\nTel: 020 7972 8128\r\nFax: 020 7972 8103\r\n\r\nE-mail:[jonathan.plumb@mhra.gsi.gov.uk](mailto:jonathan.plumb@mhra.gsi.gov.uk)\r\n\r\n"}],"max_cache_time":10,"temporary_update_type":false,"headers":[{"text":"Device","level":2,"id":"device"},{"text":"Problem","level":2,"id":"problem"},{"text":"Action","level":2,"id":"action"},{"text":"Action by","level":2,"id":"action-by"},{"text":"Distribution","level":2,"id":"distribution"},{"text":"Manufacturer contact","level":2,"id":"manufacturer-contact"},{"text":"England","level":2,"id":"england"}]},"routes":[{"path":"/drug-device-alerts/medical-device-alert-cidex-ortho-phthalaldehyde-opa-high-level-disinfectant-solution-carry-out-risk-assessment-before-use-if-there-is-no-alternative","type":"exact"}],"redirects":[],"publishing_app":"specialist-publisher","rendering_app":"government-frontend","need_ids":[],"phase":"live","analytics_identifier":null,"document_type":"medical_safety_alert","schema_name":"specialist_document","first_published_at":null,"base_path":"/drug-device-alerts/medical-device-alert-cidex-ortho-phthalaldehyde-opa-high-level-disinfectant-solution-carry-out-risk-assessment-before-use-if-there-is-no-alternative","description":"(Johnson & Johnson) repeated exposure to device after it was used to manually reprocess urological instruments may have caused hypersensitivity in some patients with a history of bladder cancer, undergoing repeated cystoscopy. (MDA/2004/022)","content_id":"83cbcd9b-5dae-48d0-b292-59bc45ed603a","locale":"en","expanded_links":{"organisations":[{"analytics_identifier":"EA63","api_path":"/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency","base_path":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","description":null,"document_type":"organisation","locale":"en","public_updated_at":"2015-06-29T14:33:29Z","schema_name":"placeholder","title":"Medicines and Healthcare products Regulatory Agency","withdrawn":false,"details":{"brand":"department-of-health","logo":{"formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","crest":"single-identity"}},"links":{}}],"finder":[{"analytics_identifier":null,"api_path":"/api/content/drug-device-alerts","base_path":"/drug-device-alerts","content_id":"1e9c0ada-5f7e-43cc-a55f-cc32757edaa3","description":"Find alerts and recalls issued by MHRA","document_type":"finder","locale":"en","public_updated_at":"2017-03-30T10:34:00Z","schema_name":"finder","title":"Alerts and recalls for drugs and medical devices","withdrawn":false,"details":{"document_noun":"alert","filter":{"document_type":"medical_safety_alert"},"format_name":"Medical safety alert","show_summaries":true,"facets":[{"key":"alert_type","name":"Alert type","type":"text","preposition":"for","display_as_result_metadata":true,"filterable":true,"allowed_values":[{"label":"Drug alert","value":"drugs"},{"label":"Medical device alert","value":"devices"},{"label":"Field safety notice","value":"field-safety-notices"},{"label":"Drug alert: company-led","value":"company-led-drugs"}]},{"key":"medical_specialism","name":"Medical specialism","type":"text","preposition":"about","display_as_result_metadata":true,"filterable":true,"allowed_values":[{"label":"Anaesthetics","value":"anaesthetics"},{"label":"Cardiology","value":"cardiology"},{"label":"Care home staff","value":"care-home-staff"},{"label":"Cosmetic surgery","value":"cosmetic-surgery"},{"label":"Critical care","value":"critical-care"},{"label":"Dentistry","value":"dentistry"},{"label":"General practice","value":"general-practice"},{"label":"General surgery","value":"general-surgery"},{"label":"Haematology and oncology","value":"haematology-oncology"},{"label":"Infection prevention","value":"infection-prevention"},{"label":"Obstetrics and gynaecology","value":"obstetrics-gynaecology"},{"label":"Ophthalmology","value":"ophthalmology"},{"label":"Orthopaedics","value":"orthopaedics"},{"label":"Paediatrics","value":"paediatrics"},{"label":"Pathology","value":"pathology"},{"label":"Pharmacy","value":"pharmacy"},{"label":"Physiotherapy and occupational therapy","value":"physiotherapy-occupational-therapy"},{"label":"Radiology","value":"radiology"},{"label":"Renal medicine","value":"renal-medicine"},{"label":"Theatre practitioners","value":"theatre-practitioners"},{"label":"Urology","value":"urology"},{"label":"Vascular and cardiac surgery","value":"vascular-cardiac-surgery"}]},{"key":"issued_date","name":"Issued","short_name":"Issued","type":"date","preposition":"issued","display_as_result_metadata":true,"filterable":true}],"default_documents_per_page":50},"links":{}}]},"format":"specialist_document","navigation_document_supertype":"other","user_journey_document_supertype":"thing","email_document_supertype":"other","government_document_supertype":"other","payload_version":0}